Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib

Academic Radiology

Volumn 23, Issue 3, 2016, Pages 329-336

  Nishino, Mizuki ^a   Dahlberg, Suzanne E ^b   Fulton, Linnea E ^c   Digumarthy, Subba R ^c   Hatabu, Hiroto ^a   Johnson, Bruce E ^a   Sequist, Lecia V ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

EGFR mutations; Lung cancer; Non small cell; Tumor volume; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH RATE; HUMAN; LUNG ADENOCARCINOMA; LUNG LESION; MALE; MISSENSE MUTATION; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VOLUMETRY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; REMISSION; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE PROGRESSION; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; YOUNG ADULT;

EID: 84959493869     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2015.11.005     Document Type: Article

References (46)

1. Kris M.G., Johnson B.E., Berry L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
2. Nishino M., Hatabu H., Johnson B.E., et al. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 2014, 271:6-27.
3. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
6. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
7. Yang K., Kim D., Planchard D., et al. Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC) 2014, ESMO.
8. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
9. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
10. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
11. Jackman D.M., Yeap B.Y., Sequist L.V., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
12. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
13. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
14. Nishino M., Guo M., Jackman D.M., et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol 2011, 18:54-62.
15. Nishino M., Jagannathan J.P., Krajewski K.M., et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012, 198:737-745.
16. Erasmus J.J., Gladish G.W., Broemeling L., et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003, 21:2574-2582.
17. Mozley P.D., Bendtsen C., Zhao B., et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol 2012, 5:19-25.
18. Mozley P.D., Schwartz L.H., Bendtsen C., et al. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol 2010, 21:1751-1755.
19. Zhao B., James L.P., Moskowitz C.S., et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 2009, 252:263-272.
20. Zhao B., Schwartz L.H., Moskowitz C.S., et al. Lung cancer: computerized quantification of tumor response-initial results. Radiology 2006, 241:892-898.
21. Nishino M., Dahlberg S.E., Cardarella S., et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 2013, 8:1059-1068.
22. Looney W.B., Trefil J.S., Hopkins H.A., et al. Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy. Proc Natl Acad Sci U S A 1977, 74:1983-1987.
23. Demicheli R., Foroni R., Ingrosso A., et al. An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res 1989, 49:6543-6546.
24. Gomez-Roca C., Koscielny S., Ribrag V., et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 2011, 47:2512-2516.
25. Stein W.D., Gulley J.L., Schlom J., et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011, 17:907-917.
26. Stein W.D., Wilkerson J., Kim S.T., et al. Analyzing the pivotal trial that compared sunitinib and IFN-alpha in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012, 18:2374-2381.
27. Ferte C., Fernandez M., Hollebecque A., et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2014, 20:246-252.
28. Nishino M., Dahlberg S.E., Cardarella S., et al. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 2013, 119:3761-3768.
29. Nishino M., Cardarella S., Dahlberg S.E., et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 79:283-288.
30. Nishino M., Cardarella S., Jackman D.M., et al. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 2013, 201:W64-W71.
31. Nishino M., Jackman D.M., DiPiro P.J., et al. Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: an exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol 2014, 69:841-848.
32. Gold K.A., Kim E.S., Lee J.J., et al. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) 2011, 4:962-972.
33. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics 1982, 38:963-974.
34. McKeage K. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer. Drugs 2015, 75:75-82.
35. Sato T., Watanabe A., Kondo H., et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg 2015, 149:64-69. 70.e1-2.
36. Kato M., Shukuya T., Takahashi F., et al. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer 2014, 14:508.
37. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
38. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
39. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
40. Seto T., Kiura K., Nishio M., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
41. Park K., Ahn M.J., Yu C.J., et al. ASPIRATION: first-line erlotinib until and beyond RECIST progression in Asian patients with EGFR mutation-positive NSCLC 2014, ESMO.
42. Soria J.C., Wu Y.L., Nakagawa K., et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015, 16:990-998.
43. Kim H.S., Kim J.H. Ideal number of target lesions per organ to measure in metastatic colorectal cancer. Oncol Lett 2014, 8:1896-1900.
44. Kim H.S., Kim J.H., Yang I. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer. Lung Cancer 2014, 85:385-389.
45. Kim H.S., Kim J.W., Kim J.H., et al. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer. Oncology 2014, 88:69-75.
46. Nishino M., Jagannathan J.P., Ramaiya N.H., et al. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010, 195:281-289.